We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Propofol Could Provide Benefits in Open Heart Surgery

By HospiMedica International staff writers
Posted on 02 Mar 2016
A new study suggests that the intravenous (IV) anesthetic propofol may offer an effective approach to protecting the heart from damage during open heart surgery, particularly amongst diabetics.

Researchers at the Vancouver Coastal Health Research Institute (VCHRI; Canada) and the University of British Columbia (UBC; Vancouver, Canada) conducted a randomized trial in 137 patients scheduled for open heart surgery employing normothermic cardiopulmonary bypass (CPB) and blood cardioplegia. More...
Study participants were stratified by diabetic status and left ventricular ejection fraction (LEVF) and randomly assigned to receive either a highly controlled, increasing dose of propofol for a focused period of time during CPB, or an isoflurane preconditioning regime. The primary endpoint was the coronary sinus concentration of 15-F2t-isoprostane (isoP).

The results showed that the patients receiving propofol experienced a greater increase in isoP levels compared with those receiving isoflurane, but a decreased incidence of low cardiac output syndrome (LCOS). The incidence of LCOS was similar between both groups in participants without type 2 diabetes mellitus (DM2), but significantly decreased in the propofol DM2 subgroup compared with the isoflurane DM2 subgroup. Propofol was also associated with fewer heart failure events. The study was published on December 31, 2015, in the Canadian Journal of Anesthesia.

“This has been the operating paradigm for years; anesthesiologists are taking advantage of an antioxidant property of propofol to stop free radical insult, which ultimately is expected to translate into improved outcomes,” said lead author David Ansley, MD, of the VCHRI and the UBC department of anesthesiology, pharmacology, and therapeutics. “Quite paradoxically, based on our research we think the drug actually stimulates a process that is pro-oxidant, rather than antioxidant, and the cells in the heart are responding to these pro-oxidant activities.”

“Originally we thought we’re protecting the heart by soaking up free radicals, but the reality is that propofol and how we administer it is actually changing the biology of the heart to a more favorable profile that protects mitochondria, keeping cell tissue alive,” continued Dr. Ansley. “We’ve found a technique that doesn’t currently exist that we actually believe will be of true benefit to diabetes patients undergoing open heart surgery.”

Propofol, discovered in 1977, is a short-acting IV anesthetic that is used for initiation and maintenance of general anesthesia, sedation for mechanically ventilated adults, and procedural sedation. It is often referred to as “milk of amnesia” because of its milk-like appearance and lack of memory of events during administration. Common side effects include an irregular heart rate, low blood pressure, burning sensation at the site of injection, and apnea. Other serious side effects may include seizures, infections, addiction, and propofol infusion syndrome with long term use.

Related Links:

Vancouver Coastal Health Research Institute
University of British Columbia



Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Floor‑Mounted Digital X‑Ray System
MasteRad MX30+
Emergency Ventilator
Shangrila935
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The AI-based approach identifies lipid regions matched well with histopathology results (Photo courtesy of Hyeong Soo Nam/KAIST)

AI-Based OCT Image Analysis Identifies High-Risk Plaques in Coronary Arteries

Lipid-rich plaques inside coronary arteries are strongly associated with heart attacks and other major cardiac events. While optical coherence tomography (OCT) provides detailed images of vessel structure... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.